October 24, 2017
United Therapeutics announces FDA approval of nebulizer for the Tyvaso Inhalation System
© Reuters. United Therapeutics announces FDA approval of nebulizer for the Tyvaso Inhalation System
- FDA approves United Therapeutics’ (NASDAQ:UTHR) new inhalation device, called the TD-300/A, for use with Tyvaso (treprostinil) Inhalation Solution.
- Tyvaso was originally approved for the treatment of pulmonary arterial hypertension (PAH) in 2009, covering a drug-device combination product consisting of Tyvaso drug product and an ultrasonic nebulizer and accessories referred to as the Tyvaso Inhalation System. The TD-300/A has a cleaner, more ergonomic design.
- Tyvaso is a prostacyclin vasodilator indicated for the treatment of PAH (WHO Group 1) to improve exercise ability.
- Now read: United Therapeutics: This Seems To Be The Time To Sell The Stock In 2017